...
机译:PD-1 / PD-L1抑制剂在晚期肝细胞癌中的临床效益:系统评价和荟萃分析
Capital Med Univ Beijing Friendship Hosp Dept Gen Surg Beijing Key Lab Canc Invas &
Metastasis;
Capital Med Univ Beijing Friendship Hosp Natl Clin Res Ctr Digest Dis Clin Epidemiol &
EBM Unit;
Capital Med Univ Beijing Friendship Hosp Dept Gen Surg Beijing Key Lab Canc Invas &
Metastasis;
Capital Med Univ Beijing Friendship Hosp Dept Gen Surg Beijing Key Lab Canc Invas &
Metastasis;
Capital Med Univ Beijing Friendship Hosp Dept Vasc Surg 95 Yong An Rd Beijing 100050 Peoples R;
Capital Med Univ Beijing Friendship Hosp Dept Gen Surg Beijing Key Lab Canc Invas &
Metastasis;
Capital Med Univ Beijing Friendship Hosp Dept Gen Surg Beijing Key Lab Canc Invas &
Metastasis;
Capital Med Univ Beijing Friendship Hosp Dept Gen Surg Beijing Key Lab Canc Invas &
Metastasis;
Capital Med Univ Beijing Friendship Hosp Dept Gen Surg Beijing Key Lab Canc Invas &
Metastasis;
PD-1; PD-L1; Monoclonal antibody; Nivolumab; Pembrolizumab; Anti-VEGF agent; Objective response rate; Disease control rate; Overall survival; Progression-free survival; Adverse event; Meta-analysis;
机译:PD-1 / PD-L1抑制剂在特定患者亚组中的系统评价和荟萃分析,具有晚期胃食性结合和胃腺癌
机译:复发性或转移性鼻咽癌患者PD-1 / PD-L1抑制剂的功效和安全性:系统审查和荟萃分析
机译:抗PD-1 / PD-L1抑制剂治疗晚期或转移性癌症的临床疗效和安全性:系统评价和荟萃分析
机译:离聚肿瘤和正常组织中检查点抑制剂(PD-1和PD-L1)的多次流式细胞术分析
机译:双语和性能与临床神经心理学测试的关系:系统评价与荟萃分析
机译:PD-1 / PD-L1抑制剂对预处理的晚期癌症的疗效:系统评价和荟萃分析
机译:单独使用PD-1 / PD-L1抑制剂治疗固体肿瘤的肝毒性,PD-1 / PD-L1抑制剂加上化疗,或单独化疗:系统评价和荟萃分析
机译:综合医疗保健研究的系统评价:随机对照试验,临床对照试验和meta分析